Steminent Biotherapeutics, Inc. (7729) Stock Statistics & Valuation Metrics
Total Valuation
Steminent Biotherapeutics, Inc. has a market cap or net worth of TWD 15.13B. The enterprise value is ―.
- Market Cap
- TWD 15.13B
- Enterprise Value
- ―
Share Statistics
Steminent Biotherapeutics, Inc. has 80,682,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 80,682,240
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Steminent Biotherapeutics, Inc.’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -25.46%.
- Return on Equity (ROE)
- -0.29
- Return on Assets (ROA)
- -0.25
- Return on Invested Capital (ROIC)
- -25.46%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.16M
- Employee Count
- 55
- Asset Turnover
- 0.00
- Inventory Turnover
- 2.05
Valuation Ratios
The current PE Ratio of Steminent Biotherapeutics, Inc. is -38.79. Steminent Biotherapeutics, Inc.’s PEG ratio is 1.25.
- PE Ratio
- -38.79
- PS Ratio
- 0.00
- PB Ratio
- 16.29
- Price to FCF
- -65.95
- Price to Operating Cash Flow
- -67.88
- PEG Ratio
- 1.25
Income Statement
In the last 12 months, Steminent Biotherapeutics, Inc. had revenue of 0 and earned -174.04M in profits. Earnings per share was -2.95.
- Revenue
- 0
- Gross Profit
- -30.92M
- Operating Income
- -172.87M
- Pretax Income
- -174.15M
- Net Income
- -174.04M
- EBITDA
- -142.74M
- Earnings Per Share (EPS)
- -2.95
Cash Flow
In the last 12 months, operating cash flow was -173.71M and capital expenditures -5.12M, giving a free cash flow of -178.83M billion.
- Operating Cash Flow
- -173.71M
- Free Cash Flow
- -178.83M
- Free Cash Flow per Share
- -3.16
Dividends & Yields
Steminent Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.55%
- Earnings Yield
- -2.24%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- 376.51%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 55.94
- Average Volume (3m)
- 1.17M
Financial Position
Steminent Biotherapeutics, Inc. as a current ratio of 13.58, with Debt / Equity ratio of 12.88%
- Current Ratio
- 13.58
- Quick Ratio
- 13.18
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 2.95
- Interest Coverage Ratio
- -80.26
Taxes
In the past 12 months, Steminent Biotherapeutics, Inc. has paid -111.00K in taxes.
- Income Tax
- -111.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Steminent Biotherapeutics, Inc. EV to EBITDA ratio is -48.43, with an EV/FCF ratio of -61.09.
- EV to Sales
- 0.00
- EV to EBITDA
- -48.43
- EV to Free Cash Flow
- -61.09
- EV to Operating Cash Flow
- -63.55
Balance Sheet
Steminent Biotherapeutics, Inc. has TWD 891.65M in cash and marketable securities with TWD 69.61M in debt, giving a net cash position of TWD 822.03M billion.
- Cash & Marketable Securities
- TWD 891.65M
- Total Debt
- TWD 69.61M
- Net Cash
- TWD 822.03M
- Net Cash Per Share
- TWD 10.19
- Tangible Book Value Per Share
- TWD 13.71
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Steminent Biotherapeutics, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -17.66%
